(Last Updated March 4, 2021)
Welcome to the news page for Pfizer Inc (PFE). Below you’ll find our daily market updates. Here’s a technical and fundamental summary of where things currently stand:
If we observe the 90, 30 and 14 day timeframes, we see a downtrend in place for PFE.
PFE’s moving averages suggest the trend on a number of time horizons is bearish.
Below is a chart showing PFE’s price with its moving averages.
The price move occurred on stronger volume; specifically, yesterday’s volume was up 66.35% from the day prior, and up 34.15% from the same day the week before.
It’s been a feast for bears operating on an hourly timeframe, as pfe has now gone down 4 of the past 5 hours.
The change in price came along side change in volume that was down 27.15% from previous day, but up 26.01% from the monday of last week.
Pfizer had the lowest reputational score among the pharmaceutical companies that reputation institute looked at, based on the general public's perception of product, prices and public hospitality.
And that would be a bargain from these $30's.
Panzyga can also be administered at infusion rates up to 12 mg/kg/min.
This is a reversal of the price action on the previous hour, in which price moved up.
It’s been a feast for bears operating on an hourly timeframe, as pfe has now gone down 4 of the past 5 hours.
(Nyse: pfe) today announced that the phase 3 spirit long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss.
Regarding the trend, note that the strongest trend exists on the 20 hour timeframe.